Over the past two decades, a substantial number of candidate proteomics biomarkers have been identified, but they have had little impact on clinical outcomes. A remaining challenge in proteomics biomarker research is “assay development”. Traditionally assay development refers to the challenge with developing an immunoassay for a selected protein – this is a difficult art associated with substantial cost and time.
Det här är ett utplock av en intressant artikel från KBN – Nr. 3 – vol. 37 – 2025.